Article info
Original research
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
- Correspondence to Professor Sandro Pignata, Gynecological Oncology, National Cancer Institute, Naples, Italy; s.pignata{at}istitutotumori.na.it
Citation
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
Publication history
- Received December 21, 2020
- Revision received April 6, 2021
- Accepted April 8, 2021
- First published May 14, 2021.
Article Versions
- You are currently viewing a Previous version of this article (14 May 2021).
- latest version (3 June 2021).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.